Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Time To Pick These 3 Top Relative Price Strength Stocks
09:02am, Tuesday, 24'th Jan 2023
Clarivate Plc (CLVT), Expedia Group (EXPE) and Haemonetics Corporation (HAE) are three stocks with explosive relative price strength.
These Two Stocks Make New Highs, Hold In Buy Zones
04:13pm, Friday, 20'th Jan 2023
New highs are rare for stocks when major indexes hit resistance. Yet HAE and LECO are climbing to 52-week highs and are in buy zones.
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
01:33pm, Thursday, 12'th Jan 2023
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023
04:05pm, Friday, 06'th Jan 2023
BOSTON , Jan. 6, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, Febru
How 2022's Biggest Healthcare Gainers Could Fare In 2023
09:30am, Friday, 06'th Jan 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
11:17am, Friday, 23'rd Dec 2022
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amen! With A Strict Moral Code, Fund's Lofty Return Is Heavenly
07:00am, Wednesday, 30'th Nov 2022
Want tips about how to invest in stocks and mutual funds? Check out $368 million Ave Maria Value Fund (AVEMX) and its 7.75% return this year.
Haemonetics Leveraging Strong Recovery Trends And Repositioning For The Future
01:14pm, Thursday, 17'th Nov 2022
Haemonetics posted another quarterly beat, with exceptionally strong results from the Plasma business as plasma-derived therapy companies look to rebuild inventories. Between a looming recession and g
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
02:49pm, Friday, 11'th Nov 2022 Zacks Investment Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst
07:37pm, Tuesday, 08'th Nov 2022 Benzinga
JMP Securities raised the price target to $105 from $90 on Haemonetics Corporation (NYSE: HAE) with a Market Outperform rating following the release of Q2 FY23 results.
The company posted Q2 EPS
Company News for Nov 8, 2022
02:26pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Companies In The News Are: HAE, AMG, NI, PLTR.
Expert Ratings for Haemonetics
01:59pm, Tuesday, 08'th Nov 2022 Benzinga
Analysts have provided the following ratings for Haemonetics (NYSE:HAE) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
3
0
0
Last 3
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
12:25pm, Monday, 07'th Nov 2022 Zacks Investment Research
Haemonetics (HAE) delivered earnings and revenue surprises of 18.57% and 8.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics Corporation (HAE) Q2 2023 Earnings Call Transcript
11:17am, Monday, 07'th Nov 2022
Haemonetics Corporation (NYSE:HAE ) Q2 2023 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Olga Guyette - Director, Investor Relations and Treasury Chris Simon - Chief Execu
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
09:04am, Monday, 07'th Nov 2022
Haemonetics (HAE) delivered earnings and revenue surprises of 18.57% and 8.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
